Role of dormancy survival regulator and resuscitation-promoting factors antigens in differentiating between active and latent tuberculosis: a systematic review and meta-analysis.
Active
Antigen
Dormancy
Laten
Resuscitation
Tuberculosis
Journal
BMC pulmonary medicine
ISSN: 1471-2466
Titre abrégé: BMC Pulm Med
Pays: England
ID NLM: 100968563
Informations de publication
Date de publication:
29 Oct 2024
29 Oct 2024
Historique:
received:
15
05
2024
accepted:
17
10
2024
medline:
30
10
2024
pubmed:
30
10
2024
entrez:
30
10
2024
Statut:
epublish
Résumé
Dormancy survival regulator (DosR) and resuscitation-promoting factor (Rpf) antigens of Mycobacterium tuberculosis are activated during dormant phase of tuberculosis (TB). This study evaluates the differential immunogenicity potentials of DosR and Rpf antigens in individuals with latent tuberculosis infection (LTBI) and active TB patients. After a literature search in electronic databases, studies were selected by following precise eligibility criteria. Outcomes were synthesized systematically, and meta-analyses were performed to estimate standardized mean differences (SMDs) in interferon-gamma (IFNγ) levels, and IFNγ positive immune cells between individuals with LTBI and active TB patients. Twenty-six studies (1278 individuals with LTBI and 1189 active TB patients) were included. DosR antigens Rv0569 (Standardized mean difference; SMD 2.44 [95%CI: 1.21, 3.66]; p < 0.0001), Rv1733c (SMD 0.60 [95%CI: 0.14, 1.07]; p = 0.011), Rv1735c (SMD 1.16 [95%CI: 0.44, 1.88]; p = 0.002), Rv1737c (SMD 1.26 [95%CI: 0.59, 1.92]; p < 0.0001), Rv2029c (SMD 0.89 [95%CI: 0.35, 1.42]; p = 0.002), RV2626c (SMD 1.24 [95%CI: 0.45, 2.02); p = 0.002), and Rv2628 (SMD 0.65 [95%CI: 0.38, 0.91]; p < 0.0001) and Rpf antigens Rv0867c (SMD 1.33 [95%CI: 0.48, 2.18]; p = 0.002), Rv1009 (SMD 0.65 [95%CI: 0.05, 1.25]; p = 0.034), and Rv2450c (SMD 1.54 [95%CI: 0.92, 2.16]; p < 0.0001) elicited higher IFNγ levels in individuals with LTBI in comparison with active TB patients. IFNγ-positive immunoresponsive cells were significantly higher in individuals with LTBI than in active TB patients for antigens Rv1733c (SMD 1.02 [95%CI: 0.15, 1.88]; p = 0.021), Rv2029c (SMD 0.57 [95%CI: 0.05, 1.09]; p = 0.031), and Rv2628 [SMD 0.38 [95%CI: 0.15, 0.61]; p = 0.001). DosR antigens Rv0569, Rv1733c, Rv1735c, Rv1737c, RV2626c, Rv2628, and Rv2029c, and Rpf antigens Rv0867c, Rv1009, and Rv2450c are found to elicit immune responses differently in individuals with LTBI and active TB patients.
Sections du résumé
BACKGROUND
BACKGROUND
Dormancy survival regulator (DosR) and resuscitation-promoting factor (Rpf) antigens of Mycobacterium tuberculosis are activated during dormant phase of tuberculosis (TB). This study evaluates the differential immunogenicity potentials of DosR and Rpf antigens in individuals with latent tuberculosis infection (LTBI) and active TB patients.
METHODS
METHODS
After a literature search in electronic databases, studies were selected by following precise eligibility criteria. Outcomes were synthesized systematically, and meta-analyses were performed to estimate standardized mean differences (SMDs) in interferon-gamma (IFNγ) levels, and IFNγ positive immune cells between individuals with LTBI and active TB patients.
RESULTS
RESULTS
Twenty-six studies (1278 individuals with LTBI and 1189 active TB patients) were included. DosR antigens Rv0569 (Standardized mean difference; SMD 2.44 [95%CI: 1.21, 3.66]; p < 0.0001), Rv1733c (SMD 0.60 [95%CI: 0.14, 1.07]; p = 0.011), Rv1735c (SMD 1.16 [95%CI: 0.44, 1.88]; p = 0.002), Rv1737c (SMD 1.26 [95%CI: 0.59, 1.92]; p < 0.0001), Rv2029c (SMD 0.89 [95%CI: 0.35, 1.42]; p = 0.002), RV2626c (SMD 1.24 [95%CI: 0.45, 2.02); p = 0.002), and Rv2628 (SMD 0.65 [95%CI: 0.38, 0.91]; p < 0.0001) and Rpf antigens Rv0867c (SMD 1.33 [95%CI: 0.48, 2.18]; p = 0.002), Rv1009 (SMD 0.65 [95%CI: 0.05, 1.25]; p = 0.034), and Rv2450c (SMD 1.54 [95%CI: 0.92, 2.16]; p < 0.0001) elicited higher IFNγ levels in individuals with LTBI in comparison with active TB patients. IFNγ-positive immunoresponsive cells were significantly higher in individuals with LTBI than in active TB patients for antigens Rv1733c (SMD 1.02 [95%CI: 0.15, 1.88]; p = 0.021), Rv2029c (SMD 0.57 [95%CI: 0.05, 1.09]; p = 0.031), and Rv2628 [SMD 0.38 [95%CI: 0.15, 0.61]; p = 0.001).
CONCLUSION
CONCLUSIONS
DosR antigens Rv0569, Rv1733c, Rv1735c, Rv1737c, RV2626c, Rv2628, and Rv2029c, and Rpf antigens Rv0867c, Rv1009, and Rv2450c are found to elicit immune responses differently in individuals with LTBI and active TB patients.
Identifiants
pubmed: 39472851
doi: 10.1186/s12890-024-03348-4
pii: 10.1186/s12890-024-03348-4
doi:
Substances chimiques
Antigens, Bacterial
0
Bacterial Proteins
0
resuscitation-promoting factor, bacteria
0
Interferon-gamma
82115-62-6
DosR protein, Mycobacterium tuberculosis
0
DNA-Binding Proteins
0
Cytokines
0
Types de publication
Journal Article
Systematic Review
Meta-Analysis
Langues
eng
Sous-ensembles de citation
IM
Pagination
541Subventions
Organisme : the Jiangxi Provincial Health Commission Science and Technology Plan
ID : Grant No: 202311367
Organisme : the Chinese People's Liberation Army Joint Logistic Support Force 908 Hospital Seed Fund
ID : Grant No: 2022YNKT006
Informations de copyright
© 2024. The Author(s).
Références
BMC Infect Dis. 2018 Jan 8;18(1):26
pubmed: 29310595
Clin Vaccine Immunol. 2009 Aug;16(8):1203-12
pubmed: 19553548
Front Microbiol. 2021 Oct 22;12:745592
pubmed: 34745048
Clin Vaccine Immunol. 2016 Oct 4;23(10):813-824
pubmed: 27489136
Semin Immunol. 2018 Oct;39:88-101
pubmed: 30327124
PLoS One. 2009;4(5):e5590
pubmed: 19440342
ACS Infect Dis. 2020 Feb 14;6(2):272-280
pubmed: 31815418
Int J Tuberc Lung Dis. 2013 Jun;17(6):818-24
pubmed: 23676169
Tuberculosis (Edinb). 2016 Mar;97:97-107
pubmed: 26980501
Infect Immun. 2007 Jul;75(7):3523-30
pubmed: 17502400
Sci Rep. 2017 Sep 20;7(1):11948
pubmed: 28931830
Tuberculosis (Edinb). 2015 Dec;95(6):751-757
pubmed: 26421415
J Infect. 2015 Aug;71(2):238-49
pubmed: 25936741
China CDC Wkly. 2020 Dec 25;2(52):995-998
pubmed: 34594823
Clin Vaccine Immunol. 2011 Apr;18(4):676-83
pubmed: 21248154
PLoS One. 2013 Sep 10;8(9):e74080
pubmed: 24040170
PLoS One. 2015 Apr 21;10(4):e0124134
pubmed: 25897840
J Infect. 2019 Apr;78(4):275-280
pubmed: 30528871
Front Immunol. 2018 Nov 09;9:2476
pubmed: 30473692
EBioMedicine. 2015 May 30;2(8):884-90
pubmed: 26425695
Front Immunol. 2020 Feb 11;11:103
pubmed: 32117257
Microbiol Res. 2021 Nov;252:126853
pubmed: 34536677
Infect Immun. 2007 Jun;75(6):2914-21
pubmed: 17387166
Front Microbiol. 2014 Oct 08;5:517
pubmed: 25339944
Eur J Clin Microbiol Infect Dis. 2022 Jul;41(7):1039-1049
pubmed: 35612766
Braz J Infect Dis. 2015 Nov-Dec;19(6):636-42
pubmed: 26358744
J Clin Med. 2023 Jul 19;12(14):
pubmed: 37510899
Sci Rep. 2020 May 4;10(1):7472
pubmed: 32366931
Front Immunol. 2020 Sep 10;11:2006
pubmed: 33013856
Front Immunol. 2017 Sep 13;8:1134
pubmed: 28955344
J Immunol Res. 2017;2017:1593143
pubmed: 28255560
Chin Med J (Engl). 2021 Nov 19;135(1):63-69
pubmed: 34802023
Front Immunol. 2017 Jun 24;8:712
pubmed: 28694808
Tuberculosis (Edinb). 2013 Nov;93(6):612-7
pubmed: 24053975
MMWR Morb Mortal Wkly Rep. 2023 Mar 24;72(12):297-303
pubmed: 36952282
Sci Rep. 2023 Apr 28;13(1):6978
pubmed: 37117690
MMWR Morb Mortal Wkly Rep. 2024 Mar 28;73(12):265-270
pubmed: 38547024
Int J Infect Dis. 2021 Sep;110:75-82
pubmed: 34284090
Eur Respir J. 2010 Jul;36(1):135-42
pubmed: 19926735
Tuberculosis (Edinb). 2017 Sep;106:25-32
pubmed: 28802401
Comp Immunol Microbiol Infect Dis. 2016 Feb;44:8-13
pubmed: 26851588
Microbes Infect. 2006 Jul;8(8):2052-60
pubmed: 16931093
Med Lav. 2020 Jun 26;111(3):170-183
pubmed: 32624559
Tuberculosis (Edinb). 2012 Mar;92(2):148-59
pubmed: 22226907
Clin Vaccine Immunol. 2006 Feb;13(2):179-86
pubmed: 16467323